Products

CogNet QmTRIAGE
MedCognetics
Oncology AI
MedCognetics CogNet QmTRIAGE is an FDA-cleared AI-powered software for breast cancer screening that triages mammography and DBT exams to prioritize suspicious cases for radiologists, aiming to improve early detection and reduce radiologist burnout.
CogNet AI-MT+
MedCognetics
Oncology AI
Medcognetics' CogNet AI-MT+ is an FDA-cleared AI-enabled radiological computer-aided triage and notification software that analyzes Digital Breast Tomosynthesis (DBT) mammograms to prioritize studies with suspicious findings, optimizing radiology workflows and supporting earlier identification of potential cancers.

See all 2 products →

About Medcognetics

MedCognetics is a healthcare AI company that develops advanced AI software platforms designed to leverage artificial intelligence and machine learning to detect the earliest manifestations of cancer, with an initial focus on breast cancer. Their technology integrates into existing radiology workflows, providing a summary view of processed case images and highlighting the location of any findings on a summary view, enabling doctors to detect and treat cancer cells more efficiently.

A key aspect of MedCognetics’ approach is its commitment to developing “unbiased AI.” Their algorithms are trained on diverse global patient datasets to mitigate data bias, ensuring that their solutions perform effectively across various ethnicities and demographics. This focus on inclusivity aims to improve health equity and address disparities in care, particularly in underserved communities and regions where diagnostic imaging resources may be scarce. Their FDA-cleared software, such as QmTRIAGE® and CogNet AI-MT+, assists radiologists by prioritizing suspicious mammography cases, thereby helping to manage heavy workloads and reduce diagnostic delays.

Focus Areas

medical imaging AI breast cancer detection lung cancer detection unbiased AI deep learning machine learning radiology workflow computer-aided triage digital breast tomosynthesis

Business Intelligence

Technologycloud-native, edge computing, deep machine learning, AI operating system, AMD Ryzen™ processors and ROCm™ open-source software platform

What Physicians Need to Know

Specialization: Breast Cancer Detection & Medical Imaging AI
Medcognetics specializes in AI-powered solutions for breast cancer detection, including 2D mammography (FFDM) and 3D digital breast tomosynthesis (DBT). Their FDA-cleared CogNet AI-MT and CogNet AI-MT+ software analyze screening mammograms to identify suspicious findings and prioritize cases. They also offer features under development like cancer detection, breast density assessment, and a patient risk analysis model.
Key Differentiator: Unbiased AI
A core differentiator for Medcognetics is its commitment to unbiased AI. Their deep-learning algorithms are trained on globally diverse datasets, including patient populations from the US, UK, Europe, Middle East, Asia, South America, and Africa. This approach aims to ensure consistent and equitable performance across various ethnicities and geographies, mitigating AI bias often found in models trained on limited demographic data.
Specialization: Radiology Workflow & Triage
Medcognetics' solutions are designed to integrate into existing radiology workflows, assisting radiologists with worklist prioritization. Their CogNet AI-MT and AI-MT+ flag suspicious cases, enabling radiologists to focus on urgent mammograms first and potentially reduce turnaround time for screening. This helps manage heavy workloads and address radiologist burnout.
Specialization: Early Cancer Detection & Image Enhancement
The company focuses on detecting the earliest manifestations of cancer. Their technology includes advanced deep learning to highlight subtle cancer patterns, aiming to improve sensitivity without increasing false alarms. Medcognetics is also developing image enhancement features such as motion suppression for contrast-enhanced digital mammography (CEDM) and microcalcification enhancement, as well as image denoising.
Specialization: Breast Density Classification & Patient Risk Scoring
Medcognetics' AI provides consistent and accurate breast density classification to support risk-based screening decisions and regulatory compliance. They also offer patient risk scoring, which uses advanced imaging biomarkers to estimate individualized breast cancer risk for more personalized screening strategies.
Technology Stack & Deployment Flexibility
Medcognetics utilizes an open stack, including AMD Ryzen™ processors and ROCm™ software, for flexible deployment across diverse platforms, from edge devices to cloud environments. They also use NVIDIA IGX Orin medical-grade edge AI platform and NVIDIA Holoscan for real-time sensor processing, or NVIDIA Tensor Core GPUs in the cloud. Their solutions can be deployed via cloud, on-premises, embedded directly into imaging devices, or through a web portal.
Global Accessibility & Mobile Screening
Medcognetics is committed to expanding global access to healthcare. Their technology is being deployed in mobile mammography vans in rural communities in India and is planned for use in parts of Africa, enabling real-time mammogram analysis and immediate diagnostic feedback in underserved areas.
Physician Tip

Medcognetics' AI solutions, such as CogNet AI-MT and AI-MT+, are designed as decision support tools to enhance radiologists' capabilities. They can help prioritize mammography cases with suspicious findings, potentially reducing review times and managing heavy workloads. The unbiased nature of their AI, trained on diverse global datasets, aims to provide reliable performance across all patient populations, promoting health equity. Physicians can leverage the AI's ability to highlight subtle cancer patterns, assist with breast density classification, and provide patient risk scores for more personalized screening strategies. The flexible deployment options (cloud, on-premises, embedded, web portal) allow for seamless integration into various clinical practices.

Medcognetics' AI solutions are designed for seamless integration into existing clinical workflows and IT systems. They collaborate with partners like Laurel Bridge Software for robust workflow and security frameworks, including secure image routing and results delivery, and Blackford Platform to offer their AI solutions to a broader network of healthcare providers. Their open technology stack facilitates deployment across diverse platforms, from edge devices to cloud environments.

Products by Medcognetics

2 products in the directory

CogNet QmTRIAGE
MedCognetics
Oncology AI
MedCognetics CogNet QmTRIAGE is an FDA-cleared AI-powered software for breast cancer screening that triages mammography and DBT exams to prioritize suspicious cases for radiologists, aiming to improve early detection and reduce radiologist burnout.
CogNet AI-MT+
MedCognetics
Oncology AI
Medcognetics' CogNet AI-MT+ is an FDA-cleared AI-enabled radiological computer-aided triage and notification software that analyzes Digital Breast Tomosynthesis (DBT) mammograms to prioritize studies with suspicious findings, optimizing radiology workflows and supporting earlier identification of potential cancers.

What the Web Says

MedCognetics is a Dallas-based company specializing in AI-powered breast cancer screening software. Their flagship product, QmTRIAGE (and its successor, CogNet AI-MT+), has received FDA 510(k) clearance and aims to improve early breast cancer detection, particularly across diverse patient populations, while also assisting radiologists with heavy workloads. The company emphasizes its commitment to combating AI bias by training its models on diverse global datasets.

Overall: Positive

Strengths

  • AI-powered software improves early breast cancer detection.
  • Designed to reduce AI bias by utilizing diverse patient datasets.
  • Helps alleviate radiologist workload and burnout by prioritizing suspicious cases.
  • Integrates into standard radiology workflows without requiring additional tasks from radiologists.
  • Offers on-premises, cloud, or web deployment options for accessibility.
  • High detection accuracy leads to reduced review time for radiologists.

Limitations

  • Limited public reviews available on platforms like G2, Glassdoor, Capterra, and Reddit specifically for MedCognetics, making it difficult to assess widespread user or employee sentiment.
  • General concerns exist in the healthcare IT space regarding AI adoption, integration with existing systems, and compliance.
  • Some studies suggest that commercially available AI for breast cancer screening may not always be superior to experienced radiologists, though AI algorithms are constantly improving.

Based on reviews from: Healthcare IT News, Built In, Reddit, pharmaphorum, AuntMinnie, Business Wire, Dallas Innovates, G2, Capterra

Last updated: 2026-10-24

Videos

News, demos, and interviews about Medcognetics.

Loading videos...

Videos load interactively. If none appear, search YouTube for Medcognetics →

View all on YouTube

Press & Coverage

Reportable News
MedCognetics Receives FDA 510(k) Clearance for CogNet AI-MT+ Radiological Computer-Aided Triage and Notification Software
MedCognetics announced it received FDA 510(k) clearance for its CogNet AI-MT+ software, an enhanced AI-enabled radiological computer-aided triage and notification tool for 3D mammography (DBT) exams.
2026-02
AuntMinnie.com
MedCognetics receives FDA clearance for CogNet AI-MT+
MedCognetics secured FDA 510(k) clearance for its CogNet AI-MT+ software platform, designed to enhance radiologists' capabilities in medical imaging through computer-aided triage and notification, particularly for digital breast tomosynthesis (DBT) exams.
2026-02
AMD Developer Blog
AI-Powered Breast Cancer Detection with AMD & MedCognetics
This article highlights MedCognetics' collaboration with AMD, leveraging AMD Ryzen™ processors and ROCm™ open-source software platform to advance breast cancer detection with screening precision and access.
2025-10
MobiHealthNews
MedCognetics Receives FDA 510(k) Clearance for Breast Cancer Screening Software
MedCognetics received FDA 510(k) clearance for its AI-powered breast cancer screening software, QmTRIAGE, which analyzes 2D full-field digital mammography to flag abnormalities for radiologists' review.
2022-12
Dallas Innovates
Dallas’ MedCognetics Gets FDA Clearance for Its AI-Enabled Breast Cancer Screening Software
Dallas-based MedCognetics announced FDA 510(k) clearance for its AI-enabled breast cancer screening software, QmTRIAGE, which integrates into radiology workflow and focuses on improving early detection for diverse patient groups.
2022-12
Business Wire
MedCognetics Awarded $750,000 Grant from NIH to Research Unbiased Artificial Intelligence for Breast Cancer Detection
MedCognetics received a $750,000 grant from the National Institutes of Health's AIM-AHEAD program to research unbiased AI for breast cancer detection, emphasizing the company's commitment to addressing health inequities.
2023-01
Built In
MedCognetics is Using AI to Take Cancer Detection to the Next Level
This article details how MedCognetics uses AI to pinpoint early signs of breast cancer, focusing on training its machine learning model in diverse patient populations to combat AI bias.
2023-03
BioSpace
MedCognetics to Deploy AI-Enabled Mobile Mammography Units in India
MedCognetics announced a collaboration with Health Within Reach Foundation (HWRF) to deploy AI-enabled mobile mammography units in India, aiming to bring critical breast cancer screening services to underserved populations.
2026-05

Frequently Asked Questions

Medcognetics offers CogNet AI-MT for full-field digital mammography (FFDM) and CogNet AI-MT+ for digital breast tomosynthesis (DBT), both FDA-cleared for triage. These AI solutions analyze mammograms, flag suspicious findings for prioritized review, and integrate into existing imaging and IT systems to optimize workflow and reduce radiologist burnout.
Medcognetics' AI algorithms are trained on a globally diverse dataset, including data from various ethnicities and geographies, to ensure unbiased performance across all patient demographics. This commitment to inclusivity helps mitigate data bias, which is crucial for accurate breast density classification and patient risk scoring.
Medcognetics aims for the earliest possible breast cancer detection by providing AI-driven enhancements that improve image clarity and detail, even beyond the physical limitations of imaging equipment. Their FDA-cleared algorithms deliver high diagnostic precision, assisting radiologists in identifying subtle anomalies and prioritizing cases that require immediate attention.
Medcognetics offers flexible deployment options, including on-premises, cloud-based, embedded in imaging devices, and via a web portal, to suit various institutional needs and data governance requirements. Their cloud-based solutions are HIPAA-compliant, and their partnerships, like with Laurel Bridge Software, ensure robust workflow and security frameworks to meet rigorous standards.
Medcognetics has established partnerships with academic institutions like the University of Texas at Dallas and the University of Texas Southwestern Medical Center, which also hold equity in the company. They also collaborate with technology providers like AMD and NVIDIA for optimized AI solutions and deployment, and with companies like Blackford Analysis and Laurel Bridge Software for broader integration and secure workflows. The company was founded in 2019 and has received grants from the National Institute of Health (NIH) for its research.

Related Companies

A2z Radiology AI is a Boston-based medical imaging AI company that develops software for comprehensive CT interpretation, initially focusing on abdomen-pelvis CT scans. The company’s primary goal is to enhance diagnostic accuracy and efficiency in medical imaging for healthcare providers by leveraging artificial intelligence. Their flagship product, a2z-Unified-Triage, is FDA-cleared radiological computer-aided triage and notification […]

Perimeter Medical Imaging AI is a medical technology company dedicated to transforming cancer surgery through the use of ultra-high-resolution, real-time, advanced imaging tools. The company’s mission is to address significant unmet medical needs in cancer surgery, particularly concerning positive margins and the resulting need for re-excisions. Their proprietary technology, including the S-Series Optical Coherence Tomography […]

SOPHiA GENETICS is a healthcare AI company that has developed a cloud-native, AI-driven SaaS platform called SOPHiA DDM™. This platform is designed to enable hospitals, clinical laboratories, academic medical centers, and biopharmaceutical companies to analyze and interpret complex genomic, radiomic, and multimodal healthcare data. The company’s mission is to democratize data-driven medicine, providing actionable insights […]

NTL Healthcare is a South Korean AI-powered women’s health company specializing in cervical cancer screening and diagnostics. The company has a history dating back to 1996 when it first introduced an analog cervical cancer reading system, Cervicography, to Korea. Since then, NTL Healthcare has evolved its technology, developing the world’s first remote uterine cervical cancer […]

Lumonus is a healthcare technology company that specializes in AI-powered solutions for cancer care, particularly in radiation oncology. The company’s core offering is the Lumonus AI platform, a digital oncology system with AI-native clinical infrastructure designed to automate and orchestrate critical oncology workflows. This platform aims to enhance the quality and speed of care delivery […]

Qure.ai is a leading healthcare AI company that leverages deep learning and artificial intelligence to revolutionize medical imaging diagnostics and make healthcare more accessible and affordable globally. The company develops AI-powered solutions for interpreting X-rays and CT scans, addressing critical health needs in areas such as lung, musculoskeletal, cardiovascular, and neurocritical health. Their technology assists […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.